News headlines about Quest Diagnostics (NYSE:DGX) have trended somewhat positive this week, according to Accern Sentiment Analysis. Accern identifies negative and positive news coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Quest Diagnostics earned a media sentiment score of 0.15 on Accern’s scale. Accern also assigned media headlines about the medical research company an impact score of 46.1423165079548 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
These are some of the news stories that may have effected Accern’s rankings:
- Quest Diagnostics Incorporated (NYSE:DGX) Hits ‘Oversold’ Based on Its RSI – First News 24 (firstnewspaper24.com)
- Goldman Sachs Group, Inc. (The) Downgrades Quest Diagnostics Incorporated (DGX) to Buy (americanbankingnews.com)
- Quest Diagnostics Incorporated (DGX) Stock Price stands -7.85% away from 20 SMA – Voice Of Analysts (analystsbuzz.com)
- Reviewing Quest Diagnostics (DGX) & Laboratory Corporation of America Holdings (LH) (americanbankingnews.com)
- Calgon Carbon Corporation (CCC) Is Attracting Massive Concentrations By Financial Ratio Analysis – Quest … – Investing News Update (investingbizz.com)
DGX has been the topic of a number of research analyst reports. UBS AG raised their target price on Quest Diagnostics from $115.00 to $123.00 and gave the company a “buy” rating in a report on Thursday, July 6th. Canaccord Genuity reaffirmed a “buy” rating and issued a $118.00 target price on shares of Quest Diagnostics in a report on Tuesday, June 13th. BidaskClub downgraded Quest Diagnostics from a “strong-buy” rating to a “buy” rating in a report on Sunday, July 16th. Zacks Investment Research raised Quest Diagnostics from a “hold” rating to a “buy” rating and set a $123.00 target price on the stock in a report on Thursday, July 27th. Finally, Bank of America Corporation raised Quest Diagnostics from a “neutral” rating to a “buy” rating and raised their target price for the company from $111.00 to $118.00 in a report on Tuesday, July 25th. Two analysts have rated the stock with a sell rating, nine have given a hold rating and seven have given a buy rating to the stock. The company has an average rating of “Hold” and a consensus price target of $110.41.
Shares of Quest Diagnostics (NYSE DGX) opened at 90.86 on Wednesday. The firm has a market cap of $12.39 billion, a P/E ratio of 18.31 and a beta of 0.66. The company’s 50 day moving average price is $101.50 and its 200 day moving average price is $104.98. Quest Diagnostics has a 12-month low of $79.12 and a 12-month high of $112.97.
Quest Diagnostics (NYSE:DGX) last released its earnings results on Tuesday, July 25th. The medical research company reported $1.55 EPS for the quarter, beating the Zacks’ consensus estimate of $1.42 by $0.13. The business had revenue of $1.94 billion for the quarter, compared to analysts’ expectations of $1.94 billion. Quest Diagnostics had a return on equity of 15.66% and a net margin of 9.28%. The firm’s revenue was up 1.9% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.34 earnings per share. Equities research analysts forecast that Quest Diagnostics will post $5.66 EPS for the current year.
The company also recently announced a quarterly dividend, which will be paid on Wednesday, October 18th. Investors of record on Tuesday, October 3rd will be paid a $0.45 dividend. The ex-dividend date of this dividend is Monday, October 2nd. This represents a $1.80 dividend on an annualized basis and a yield of 1.98%. Quest Diagnostics’s dividend payout ratio is presently 36.29%.
In related news, Chairman Stephen H. Rusckowski sold 59,235 shares of the stock in a transaction on Tuesday, September 12th. The stock was sold at an average price of $108.16, for a total value of $6,406,857.60. Following the transaction, the chairman now owns 220,049 shares of the company’s stock, valued at $23,800,499.84. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Jeffrey M. Leiden sold 1,304 shares of the stock in a transaction on Thursday, July 27th. The shares were sold at an average price of $108.73, for a total value of $141,783.92. Following the completion of the transaction, the director now directly owns 6,296 shares in the company, valued at approximately $684,564.08. The disclosure for this sale can be found here. In the last three months, insiders sold 161,996 shares of company stock worth $17,517,207. 1.75% of the stock is owned by insiders.
Quest Diagnostics Company Profile
Quest Diagnostics Incorporated is a provider of diagnostic information services. The Company operates through two businesses: Diagnostic Information Services and Diagnostic Solutions. The Diagnostic Information Services business develops and delivers diagnostic testing information and services, providing insights that empower and enable a range of customers, including patients, clinicians, hospitals, integrated delivery networks (IDNs), health plans, employers and accountable care organizations (ACOs).
Receive News & Ratings for Quest Diagnostics Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest Diagnostics Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.